Core Insights - Esperion Therapeutics reported a quarterly loss of $0.16 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, marking a surprise of -77.78% [1] - The company achieved revenues of $87.31 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 4.75% and showing significant growth from $51.63 million a year ago [2] - Esperion's stock has increased by approximately 33.6% since the beginning of the year, outperforming the S&P 500's gain of 15.6% [3] Earnings Outlook - The earnings outlook for Esperion is mixed, with the current consensus EPS estimate for the upcoming quarter at $0.10 on revenues of $137.02 million, and for the current fiscal year at -$0.05 on revenues of $365.54 million [7] - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Drugs industry, to which Esperion belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - The performance of Esperion's stock may be influenced by the overall industry outlook and trends in earnings estimate revisions [5][8]

分组1 - electroCore, Inc. reported a quarterly loss of $0.4 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.36, and compared to a loss of $0.31 per share a year ago, indicating an earnings surprise of -11.11% [1] - The company posted revenues of $8.69 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 10.69%, and showing an increase from $6.55 million in the same quarter last year [2] - electroCore shares have declined approximately 69.5% since the beginning of the year, contrasting with the S&P 500's gain of 15.1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.26 on revenues of $8.89 million, and for the current fiscal year, it is -$1.59 on revenues of $30.84 million [7] - The Zacks Industry Rank for Medical - Drugs is currently in the top 40% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8]

Core Insights - Momentum investing focuses on following a stock's recent price trends, with the aim of buying high and selling higher, capitalizing on established price movements [1] - Relay Therapeutics, Inc. (RLAY) currently holds a Momentum Style Score of B, indicating a favorable position in momentum investing [3][12] - The Zacks Rank for Relay Therapeutics is 2 (Buy), suggesting strong potential for outperformance in the market [4][12] Price Performance - RLAY shares have increased by 5.7% over the past week, while the Zacks Medical - Drugs industry remained flat during the same period [6] - Over the last month, RLAY's price change is 42.2%, significantly outperforming the industry's 0.47% [6] - In the past quarter, RLAY shares have risen by 102.19%, and they are up 22.39% over the last year, compared to the S&P 500's increases of 7.9% and 19.67%, respectively [7] Trading Volume - RLAY's average 20-day trading volume is 1,878,524 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the last two months, one earnings estimate for RLAY has increased, while none have decreased, leading to a consensus estimate improvement from -$1.62 to -$1.59 [10] - For the next fiscal year, one estimate has moved upwards with no downward revisions, indicating positive earnings momentum [10]

Company Performance - Durect (DRRX) reported a quarterly loss of $0.07 per share, better than the Zacks Consensus Estimate of a loss of $0.13, representing an earnings surprise of +46.15% [1] - The company posted revenues of $0.45 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 39.69%, although this is a decline from year-ago revenues of $2.17 million [2] - Over the last four quarters, Durect has surpassed consensus EPS estimates two times and topped consensus revenue estimates once [2] Stock Performance - Durect shares have increased approximately 149.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.4% [3] - The current Zacks Rank for Durect is 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.18 on $0.3 million in revenues, and for the current fiscal year, it is -$0.66 on $1.19 million in revenues [7] - The outlook for the Medical - Drugs industry, where Durect operates, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Company Overview - BeOne Medicines Ltd. - Sponsored ADR (ONC) shares increased by 4% to $290.35 in the last trading session, with a notable trading volume that exceeded the average [1] - The stock has experienced a 10.4% gain over the past four weeks, indicating positive momentum [1] Sales Growth Potential - The recent stock price rally is driven by investor optimism regarding the sales growth potential of the company's oncology products, including Brukinsa (zanubrutinib) and Tevimbra (tislelizumab) [2] - BeOne Medicines is also developing several other pipeline candidates aimed at treating various cancer indications [2] Earnings and Revenue Expectations - The company is projected to report quarterly earnings of $0.19 per share, reflecting a year-over-year increase of 116.5% [3] - Expected revenues for the upcoming quarter are $1.23 billion, which represents a 32.7% increase compared to the same quarter last year [3] Earnings Estimate Revisions - The consensus EPS estimate for BeOne Medicines has been revised down by 60.7% over the last 30 days [4] - A negative trend in earnings estimate revisions typically does not lead to price appreciation, suggesting caution for future stock performance [4] Industry Context - BeOne Medicines is part of the Zacks Medical - Drugs industry, which includes other companies like Metagenomi (MGX) [5] - Metagenomi's stock closed 1.4% higher at $2.13, with a notable return of 41.9% over the past month [5] - Metagenomi's consensus EPS estimate has remained unchanged at -$0.68, representing a year-over-year change of -134.5% [6]

Company Overview - ProKidney Corp. (PROK) currently holds a Momentum Style Score of A, indicating strong momentum characteristics [3] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to the market [4] Price Performance - Over the past week, PROK shares have surged by 612.49%, significantly outperforming the Zacks Medical - Drugs industry, which increased by 1.75% [6] - In a longer timeframe, PROK's monthly price change is 292.82%, compared to the industry's 1.25% [6] - Over the past quarter, shares of PROK have increased by 349.87%, and they have gained 39.83% in the last year, while the S&P 500 has only moved 16.04% and 12.11%, respectively [7] Trading Volume - The average 20-day trading volume for PROK is 36,681,320 shares, which is a useful indicator of market interest and momentum [8] Earnings Outlook - In the past two months, one earnings estimate for PROK has moved higher, while none have moved lower, resulting in an increase in the consensus estimate from -$0.52 to -$0.49 [10] - For the next fiscal year, one estimate has also moved upwards with no downward revisions during the same period [10] Conclusion - Considering the strong price performance, trading volume, and positive earnings outlook, PROK is positioned as a promising momentum pick with a Momentum Score of A and a Zacks Rank of 2 (Buy) [12]

Company Performance - Vivos Therapeutics, Inc. reported a quarterly loss of $0.45 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.44, and an improvement from a loss of $1.63 per share a year ago [1] - The company posted revenues of $3.02 million for the quarter, missing the Zacks Consensus Estimate by 18.49%, and down from $3.42 million in the same quarter last year [2] - Over the last four quarters, Vivos Therapeutics has surpassed consensus EPS estimates two times, but has not beaten consensus revenue estimates [2] Stock Performance - Vivos Therapeutics shares have declined approximately 29.1% since the beginning of the year, contrasting with the S&P 500's gain of 0.2% [3] - The current Zacks Rank for Vivos Therapeutics is 5 (Strong Sell), indicating expectations for the stock to underperform the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.39 on revenues of $4.2 million, and for the current fiscal year, it is -$1.54 on revenues of $16.6 million [7] - The trend for estimate revisions ahead of the earnings release has been unfavorable, which may impact future stock performance [6] Industry Context - The Medical - Drugs industry, to which Vivos Therapeutics belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a relatively strong industry performance [8]

Core Viewpoint - Aclaris Therapeutics reported a quarterly loss of $0.12 per share, outperforming the Zacks Consensus Estimate of a loss of $0.17, and showing improvement from a loss of $0.24 per share a year ago, indicating a positive earnings surprise of 29.41% [1] Financial Performance - The company posted revenues of $1.46 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 65.15%, compared to revenues of $2.4 million in the same quarter last year [2] - Over the last four quarters, Aclaris has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Aclaris shares have declined approximately 49.6% since the beginning of the year, contrasting with the S&P 500's decline of 4.3% [3] - The current Zacks Rank for Aclaris is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $4.28 million, and for the current fiscal year, it is -$0.71 on revenues of $17.33 million [7] - The trend of estimate revisions for Aclaris is mixed, which could change following the recent earnings report [6] Industry Context - The Medical - Drugs industry, to which Aclaris belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Plus Therapeutics, is expected to report a quarterly loss of $0.17 per share, with a year-over-year change of +77.3% [9]